PREPARE

A phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of pembrolizumab + axitinib or avelumab + axitinib in first line therapy

III

interventionell

National

Sunitinib, Pembrolizumab, Axitinib, Avelumab

Status: In Rekrutierung

Zeitraum

2017

2023

Zentren

100

Zentren gesucht

Patienten

430

73

11.04.2022

Klinische Settings

1st line

palliativ

Beteiligte

AIO-Arbeitsgruppen

Sponsor

AIO-Studien-gGmbH

Förderer

Pfizer

Identifier

AIO-NZK-0115ass

AIO-NZK-0115ass

2016-000399-28

Kontakt

Leitung

Prof. Dr. med. Viktor Grünwald

Ansprechpartner*in

Johanna Homfeld
Telefon +49 30 814534472
E-Mail PREPARE@aio-studien-ggmbh.de